Sinus and Surgical Endoscopic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Endocrinology, Mashhad University of Medical Sciences, Mashhad, Iran.
Eur Arch Otorhinolaryngol. 2019 Oct;276(10):2797-2801. doi: 10.1007/s00405-019-05546-x. Epub 2019 Jul 22.
In this study, we aimed to determine whether short-term (2 months) vitamin D supplementation could improve the allergic symptoms in AR patients.
A randomized double-blind placebo-controlled clinical trial was performed on allergic rhinitis patients with vitamin D deficiency from Nov. 2017-2018. 80 cases with allergic rhinitis and vitamin D deficiency were divided into two groups and vitamin D plus routine antihistamine medication (cetirizine) was prescribed for the study group, whereas the control group received cetirizine plus placebo. The clinical symptoms questionnaire was completed at baseline and after 4 and 8 weeks of treatment initiation. Vitamin D levels were re-measured at the end of the 8-week treatment course.
In total, 80 patients with allergic rhinitis and vitamin D deficiency were enrolled. Among them, 35 cases and 33 controls visited the clinic after 8 weeks; the mean age in the aforementioned groups was 29.68 years and 29.13 years demonstrating no meaningful difference (P > 0.05). At study initiation, the mean vitamin D level was 14 ng/ml and 14.67 ng/ml in the study and control groups, respectively, indicating no significant difference (P = 0.189). The mean serum vitamin D level at 8 weeks of treatment in the study group (24.08 ng/ml) indicated a statistically meaningful difference with the mean vitamin D level at baseline (P < 0.001). Comparison of the mean scores of symptoms severity showed no significant difference between the two groups at study initiation and 4 weeks later (P = 0.073), whereas a significant difference was obtained between baseline and 8 weeks of treatment initiation (P = 0.007).
Based on the findings of the present study, it can be concluded that vitamin D supplementation along with antihistamines can result in relative symptoms improvement in AR patients with vitamin D deficiency.
本研究旨在探讨短期（2 个月）维生素 D 补充是否能改善 AR 患者的过敏症状。
2017 年 11 月至 2018 年，我们对患有维生素 D 缺乏的过敏性鼻炎患者进行了一项随机、双盲、安慰剂对照的临床试验。80 例过敏性鼻炎合并维生素 D 缺乏患者被分为两组，研究组给予维生素 D 联合常规抗组胺药物（西替利嗪）治疗，对照组给予西替利嗪联合安慰剂治疗。在基线时和治疗开始后 4 周和 8 周时完成临床症状问卷。在 8 周治疗结束时再次测量维生素 D 水平。
共纳入 80 例过敏性鼻炎合并维生素 D 缺乏患者。其中，35 例和 33 例研究组和对照组在 8 周后就诊；两组的平均年龄分别为 29.68 岁和 29.13 岁，差异无统计学意义（P>0.05）。研究开始时，研究组和对照组的平均维生素 D 水平分别为 14ng/ml 和 14.67ng/ml，差异无统计学意义（P=0.189）。治疗 8 周后，研究组血清维生素 D 水平均值（24.08ng/ml）与基线水平相比差异有统计学意义（P<0.001）。两组在研究开始时和 4 周后症状严重程度评分的平均值比较差异无统计学意义（P=0.073），而与基线相比差异有统计学意义（P=0.007）。
根据本研究的结果，可以得出结论，维生素 D 补充联合抗组胺药可使维生素 D 缺乏的 AR 患者的症状相对改善。
